Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
NCT ID NCT07695259
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study tests whether adding the drug olaparib to standard trastuzumab and pertuzumab before surgery can improve outcomes for women aged 60 and older with HER2-positive breast cancer. Participants receive the combination for up to six cycles before surgery, and doctors check how much the tumor shrinks. The goal is to see if this approach leads to a higher rate of complete cancer clearance in the breast at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olaparib combined with trastuzumab and pertuzumab
- What this could lead to
- If successful, this combination could offer a more effective pre-surgery treatment option for elderly patients with HER2-positive breast cancer, potentially increasing the chance of a complete response.
- What could go wrong
- This is a small, single-center Phase 4 study with only 45 participants, so results may not apply broadly. The drug combination may cause side effects like fatigue, nausea, or blood cell changes, and not all patients will respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELDERLY FEMALES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- Blood test may reveal if breast cancer treatment is working
- New targeted pill could boost lung cancer surgery success
- AI model could help doctors predict bladder cancer treatment outcomes
- New vaccine combo aims to supercharge immune attack on breast cancer